Each of us cares about someone who will need medicines.
Our pipeline.
Molecule
Therapeutic Area
Stage of Development
Molecule
ABCL635
Therapeutic Area
Endocrinology / Women's Health
Stage of Development
Discovery
IND-Enabling
Phase 1
Phase 2
Phase 3
Target
NK3R
GPCR
Indication
Vasomotor Symptoms (VMS)
Overview
ABCL635 is a potential first-in-class antibody medicine for the non-hormonal treatment of VMS (commonly known as hot flashes) associated with menopause. ABCL635 specifically targets NK3R, a clinically validated complex membrane protein found on KNDy neurons in the infundibular nucleus of the hypothalamus that helps regulate body temperature. ABCL635 is the first AbCellera-led program generated using our GPCR and ion channel technologies. It is currently being studied in a phase 1/2 trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and the frequency and severity of VMS with subcutaneous doses of ABCL635.
ABCL575 is an investigative monoclonal antibody for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications to other inflammatory and autoimmune conditions. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. It has been engineered with a modified Fc domain to support Fc-silencing and half-life extension. In preclinical studies, ABCL575 shows potent inhibition of T cell-mediated inflammatory pathways, favorable tolerability, and an in vivo half-life that is expected to support less frequent dosing than current clinical-stage molecules. A phase 1 clinical trial was initiated in Q3 of 2025 to assess safety and tolerability in healthy participants following subcutaneous doses of ABCL575.
ABCL688 is a potential antibody medicine targeting a multipass complex membrane protein for the treatment of an undisclosed indication in autoimmunity. ABCL688 is the second AbCellera-led program generated using our GPCR and ion channel technologies, and the program entered IND-enabling studies in Q2 of 2025.
This is a place that exists to push the limits of science and technology. A place focused on delivering breakthrough medicines that alleviate suffering, extend lives, and improve health.
With purpose.
In the end, our success will be measured by the impact of our medicines.
AbCellera’s commitment to people, teams, and relationships is what drew me towards the company. I’m surrounded by brilliant, kind, and down-to-earth people every day, and I’m excited to contribute to this team.
Allie Goodman
Associate Scientific Director
Our family relocated to Vancouver from Boston — it’s a great place to raise our kids. We’re big hikers, bikers, and skiers, and take every chance we get to drive 25 min to the mountains and go on an adventure!
Peri Selevos
Senior Scientist
I love being part of a team where everyone’s ideas are heard. We work together to solve problems and make things happen, which makes coming to work something I actually look forward to—even on Mondays!
Callum Costello
Scientist I
There’s a tangible impact from the work I do as we move towards bringing medicines to patients. And I get to do that inspirational work in Vancouver, where I’m surrounded by incredible nature!
14+ Years
We have grown from six scientists in a lab to a company of ~600 people with fully integrated capabilities for creating first-in-class and best-in-class antibody medicines.
100+ Programs
Since 2015, we have worked with more than 40 partners on 100+ antibody drug programs, solving some of the most difficult problems in the industry.
One Platform
We have built a competitive advantage in the creation of antibody-based medicines. We are using our technology platform to advance programs involving complex transmembrane proteins, bispecifics, and antibody drug conjugates.
